Omega Pharma, the specialist in over-the-counter medicines and healthcare products

Omega Pharma markets health and personal care products to which the end-consumer has access without a medical prescription (Over-The-Counter/OTC). With its innovative products, Omega Pharma aims to offer consumers the possibility of pursuing a healthy lifestyle and experiencing a better sense of well-being.



Dublin, Ireland — (November 6, 2014) — Perrigo Company plc (NYSE: PRGO; TASE), a leading global provider of “Quality Affordable Healthcare Products®,” and Omega Pharma NV, one of the largest OTC healthcare companies in Europe, headquartered in Nazareth, Belgium, today announced that they have entered into a definitive agreement in which Perrigo has agreed to acquire Omega for €3.6 billion, or $4.5 billion, comprised of the purchase of Omega’s equity for €2.48 billion and the assumption of €1.1 billion in debt. The transaction, funded through a combination of cash, debt, and equity, will enhance Perrigo’s leading OTC product offering and expand its distribution through Omega’s strong established platform.


April 3rd, 2014: Publication of the full IFRS Annual Report 2013

The full IFRS Annual Report 2013 has been published in Investors section


National Cycling Championship 2013

Last weekend, 5 cyclists of Omega Pharma – Quick-Step won the national title. Mark Cavendish (ENG) and Michal Kwiatskowski (POL) on the road and Tony Martin (DUI), Sylvain Chavanel (FRA) and Peter Velits (SLO) in the time trial.



Davitamon Classic 2013 attracted 8340 cycling amateurs

The 7th edition of the Davitamon Classic was again a big success! More than 350 volunteers provided the 8340 participating cycling amateurs a tremendous day! The Davitamon Classic is one of the most renowned cycling events for amateurs in Belgium. Omega Pharma is a very proud sponsor of this event, and used the occasion to highlight its Davitamon, Etixx and Bodysol products.


Over €1 billion sales in 2012!

  • 5 March 2013. publication of Condensed Annual Report 2012.
  • 15 March 2013. Publication of the full  IFRS Annual Report 2012.


Arterin strengthens product portfolio of Omega Pharma

28 February 2013. Omega Pharma announces the acquisition of Arterin, Belgian market leader in natural food supplements for managing the cholesterol level.




New segments

Omega Pharma plans to build a strong presence in key segments of the OTC market where the company was not competing until recently. In the course of 2012, Omega Pharma acquired two strong brands for the analgesics segment (pain relief products): Solpadeine and Optalidon. Solpadeine is a well-known pain relief brand, mainly in the UK, Ireland and Poland, while Optalidon benefits from a strong reputation in Italy, but is also available on the market in Belgium, Spain and Germany. In the course of 2013, Omega Pharma also intends to introduce a new range for gastro-intestinal ailments in may countries. More information will follow soon


A new dimension

The company was founded 25 years ago. The first 13 years, Omega Pharma focused exclusively on its home market, Belgium, where it built a strong network with the pharmacists. As of 2000, Omega Pharma decided to expand abroad.
Between 2000 and 2009, Omega Pharma transformed itself from a Belgian company into a multinational organization with direct operations in 35 countries.
Today, Omega Pharma is building an organization with a new dimension. We spare no effort to become a top player in the European OTC sector with a portfolio of strong international brands, a streamlined and well integrated organization and a clear vision.
Check out our Heritage.